GCC real world evidence solutions market report size, share, growth drivers, trends, opportunities & forecast 2025–2030

GCC Real World Evidence Solutions Market Overview

• The GCC Real World Evidence Solutions Market is valued at USD 2.5 billion, based on a five-year historical analysis. This reflects the region's rapid adoption of data-driven healthcare strategies and aligns with the latest global market sizing for real world evidence solutions, which is estimated between USD 2.3 billion and USD 3.3 billion for comparable regions and market segments. Growth is primarily driven by the increasing demand for data-backed insights in healthcare, the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, and the need for cost-effective healthcare delivery. The integration of advanced technologies—including artificial intelligence, big data analytics, and digital health platforms—continues to propel market expansion, enabling stakeholders to optimize clinical outcomes and operational efficiency.
• Key players in this market includeSaudi Arabiaand theUnited Arab Emirates (UAE), which dominate due to robust healthcare infrastructure, substantial investments in health technology, and a strategic focus on personalized medicine. Both countries have accelerated digital transformation in healthcare, with major pharmaceutical and biotechnology companies leveraging real-world evidence to enhance drug development, regulatory submissions, and market access strategies. The region's leadership is further supported by government initiatives promoting health data interoperability and clinical research partnerships.
• In 2023, the UAE government enacted theMinisterial Decision No. 28 of 2023 on the Use of Real-World Data in Clinical Trials and Post-Market Surveillance, issued by theMinistry of Health and Prevention (MOHAP). This regulation mandates the integration of real-world evidence in clinical trials and post-market surveillance for pharmaceuticals and medical devices. It requires healthcare providers and sponsors to utilize comprehensive data analytics, including electronic health records and patient registries, to improve patient safety and treatment outcomes. The regulation establishes operational standards for data collection, reporting, and compliance, thereby enhancing the overall quality of healthcare services across the UAE and setting a precedent for the broader GCC region.

GCC Real World Evidence Solutions Market Segmentation

By Type:The market is segmented into Observational Studies, Patient Registries, Claims Data Analysis, Electronic Health Records (EHR), Digital Health Platforms, Genomics & Biomarker Data, and Others. Each sub-segment plays a pivotal role in generating actionable insights for healthcare decision-making. Observational studies and patient registries are widely used for post-market surveillance and outcomes research, while claims data analysis and EHRs support real-time monitoring and population health management. Digital health platforms and genomics data are increasingly utilized for precision medicine and advanced analytics.

By End-User:The end-user segmentation includes Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers, Payers (Insurance Companies, Government Health Authorities), Contract Research Organizations (CROs), Academic & Research Institutes, and Others. Pharmaceutical and biotechnology firms are the largest adopters, leveraging real-world evidence for regulatory submissions and market access. Healthcare providers utilize RWE for clinical decision support and quality improvement, while payers and government authorities increasingly rely on RWE for reimbursement and policy decisions. CROs and academic institutes contribute through research collaborations and data analytics services.

GCC Real World Evidence Solutions Market Competitive Landscape

The GCC Real World Evidence Solutions Market is characterized by a dynamic mix of regional and international players. Leading participants such as IQVIA, Optum, Syneos Health, Parexel International, Medpace, Labcorp (formerly Covance), PPD (part of Thermo Fisher Scientific), Oracle Health (formerly Cerner Corporation), Flatiron Health, Aetion, Evidera (a PPD business, part of Thermo Fisher Scientific), HealthCore, Cegedim Health Data, ICON plc, Verily Life Sciences contribute to innovation, geographic expansion, and service delivery in this space.

GCC Real World Evidence Solutions Market Industry Analysis

Growth Drivers

• Increasing Demand for Patient-Centric Data:The GCC region is witnessing a significant shift towards patient-centric healthcare, with a projected increase in patient engagement initiatives. In future, healthcare expenditure in the GCC is expected to reach approximately $104.6 billion, driven by the need for personalized treatment plans. This demand is further supported by the World Health Organization's emphasis on integrating patient feedback into healthcare systems, which is anticipated to enhance the quality of care and improve health outcomes across the region.
• Advancements in Data Analytics Technologies:The rapid evolution of data analytics technologies is transforming the healthcare landscape in the GCC. In future, the healthcare analytics market in the region is projected to exceed $1.8 billion, fueled by innovations in artificial intelligence and machine learning. These technologies enable healthcare providers to analyze vast amounts of patient data efficiently, leading to improved decision-making and enhanced patient outcomes, thereby driving the adoption of real-world evidence solutions.
• Rising Focus on Value-Based Healthcare:The GCC countries are increasingly adopting value-based healthcare models, which prioritize patient outcomes over service volume. In future, it is estimated that approximately 35% of healthcare providers in the region will implement value-based care initiatives. This shift is supported by government policies aimed at improving healthcare quality and efficiency, encouraging the use of real-world evidence to assess treatment effectiveness and optimize resource allocation in healthcare systems.

Market Challenges

• Data Privacy and Security Concerns:As the adoption of real-world evidence solutions increases, so do concerns regarding data privacy and security. In future, it is projected that data breaches in the healthcare sector could cost the GCC region over $1 billion. This financial impact, coupled with stringent data protection regulations, poses a significant challenge for healthcare organizations seeking to implement real-world evidence solutions while ensuring compliance and safeguarding patient information.
• Integration Issues with Existing Systems:Many healthcare providers in the GCC face challenges integrating new real-world evidence solutions with their existing IT infrastructure. In future, it is estimated that around 55% of healthcare organizations will struggle with interoperability issues, leading to inefficiencies and increased operational costs. This challenge hinders the seamless flow of data and limits the potential benefits of real-world evidence in enhancing patient care and operational efficiency.

GCC Real World Evidence Solutions Market Future Outlook

The future of the GCC real-world evidence solutions market appears promising, driven by technological advancements and a growing emphasis on patient-centric care. As healthcare providers increasingly adopt digital health solutions, the integration of artificial intelligence and real-time data analytics will enhance decision-making processes. Furthermore, collaboration between healthcare organizations and academic institutions is expected to foster innovation, leading to improved patient outcomes and more efficient healthcare delivery systems across the region.

Market Opportunities

• Expansion of Digital Health Solutions:The digital health market in the GCC is projected to reach approximately $4.5 billion in future, presenting significant opportunities for real-world evidence solutions. This growth is driven by increased smartphone penetration and the rising adoption of telehealth services, enabling healthcare providers to collect and analyze patient data more effectively.
• Collaborations with Academic Institutions:Partnerships between healthcare organizations and academic institutions are expected to grow, with over 25 collaborative projects anticipated in future. These collaborations will facilitate research and development in real-world evidence methodologies, enhancing the quality of healthcare services and fostering innovation in treatment approaches across the GCC.